Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Improved operating performance by reducing net loss by $52.5 million; reported net loss of$4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.Significantly improved financial position by eliminating nearly all of its liabilities; reported$10.5 million as of September 30, 2024, and $99.9 million as of December 31, 2023.$10 billion+, representing Tevogen’s IP and product assets based on internal discounted cash flow models, is not reflected on the company b ...